TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35941076

Group type: EXPERIMENTAL
Intervention: Higher HBsAg levels
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Higher HBV RNA levels
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Higher HBcrAg levels
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Flares (defined as ALT ≥5xULN)
Number of subjects: 344
Study: 35941212

Group type: EXPERIMENTAL
Intervention: High dose blinatumomab (maximum 112 mcg/d after initial weekly dose escalation) for 8 weeks induction and 4 weeks consolidation.
Number of subjects: 9
Study: 35941284

Group type: EXPERIMENTAL
Intervention: 30% peak power output workload
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 80% peak power output workload
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both workloads
Number of subjects: 12
Study: 35941333

Group type: EXPERIMENTAL
Intervention: SLIDE system
Number of subjects: 76

Group type: COMPARATOR
Intervention: Manual palpation
Number of subjects: 76
Study: 35941372

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5.4 mg/kg bodyweight intravenously once every 3 weeks)
Number of subjects: 15
Study: 35941514

Group type: EXPERIMENTAL
Intervention: BPTB graft
Number of subjects: 77

Group type: COMPARATOR
Intervention: Other graft types (hamstring autograft or allografts)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: All graft types
Number of subjects: 77
Study: 35941609

Group type: EXPERIMENTAL
Intervention: Formulation 3 (MMT peel powder)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (glucose)
Number of subjects: 30
Study: 35941641

Group type: EXPERIMENTAL
Intervention: NIV after extubation
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: CatBoost machine-learning model
Number of subjects: 929
Study: 35941653

Group type: EXPERIMENTAL
Intervention: Conventional care supported by eHealth (tablet)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: eHealth (tablet)
Number of subjects: 25
Study: 35941696

Group type: EXPERIMENTAL
Intervention: UC-MSCs
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BM-MSCs
Number of subjects: 28

Group type: COMPARATOR
Intervention: UC-MSCs and BM-MSCs
Number of subjects: 28
Study: 35942082

Group type: EXPERIMENTAL
Intervention: AcrySof IQ Vivity intraocular lens (DFT015)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard aspheric monofocal intraocular lens (SN60WF)
Number of subjects: 0
Study: 35942508

Group type: EXPERIMENTAL
Intervention: Galectin-3 in Stage A/B
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Endothelin-1 in Stage A/B
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP) in Stage A/B
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP) in Stage C/D
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Soluble urokinase-type plasminogen activator receptor (suPAR) in Stage C/D
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) in Stage C/D
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Higher biomarker concentrations in Stages A/B and C/D
Number of subjects: 1235
Study: 35942530

Group type: EXPERIMENTAL
Intervention: 22 μM Lacripep
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 44 μM Lacripep
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 204
Study: 35942675

Group type: EXPERIMENTAL
Intervention: Presence of GJA1 variants
Number of subjects: 966

Group type: COMPARATOR
Intervention: Beta-blocker intake
Number of subjects: 966

Group type: COMPARATOR
Intervention: Atrial fibrillation
Number of subjects: 966

Group type: COMPARATOR
Intervention: Left ventricular ejection fraction >50%
Number of subjects: 966
Study: 35943114

Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty
Number of subjects: 4028
Study: 35943168

Group type: EXPERIMENTAL
Intervention: Precision cancer medicine (PCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 35943272

Group type: EXPERIMENTAL
Intervention: Prolonged weaning group
Number of subjects: 915
Study: 35943448

Group type: EXPERIMENTAL
Intervention: Low-oxalate diet (LOD) for 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 35943786

Group type: EXPERIMENTAL
Intervention: PointCheck (noninvasive device for neutropenia screening)
Number of subjects: 154
Study: 35943868

Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
Number of subjects: 0
Study: 35943899

Group type: EXPERIMENTAL
Intervention: Basal insulin (BI) plus oral hypoglycemic drugs (OADs)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Premixed insulin plus oral hypoglycemic drugs (OADs)
Number of subjects: 297
Study: 35944181

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing for DHCWs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing for patients
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Laboratory-based (LAB) testing for DHCWs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Laboratory-based (LAB) testing for patients
Number of subjects: 4
Study: 35944273

Group type: EXPERIMENTAL
Intervention: Hospice care
Number of subjects: 0
Study: 35944349

Group type: EXPERIMENTAL
Intervention: Single-port thoracoscopic sympathicotomy (SPTS) on the left side at the third rib (R3)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single-port thoracoscopic sympathicotomy (SPTS)
Number of subjects: 8
Study: 35944376

Group type: EXPERIMENTAL
Intervention: Gut-Cued Eating (GCE)
Number of subjects: 30
Study: 35944767

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) treatment
Number of subjects: 200
Study: 35944889

Group type: EXPERIMENTAL
Intervention: S-ICD implantation
Number of subjects: 1637
Study: 35944904

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 278
Study: 35945122

Group type: EXPERIMENTAL
Intervention: Ultrasonographic imaging in patients with PD
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 50
Study: 35945244

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel with carboplatin followed by concomitant FHX (infusional 5-fluorouracil, hydroxyurea and twice-daily radiation therapy) plus nab-paclitaxel at a dose of 100 mg/m
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel with FHX
Number of subjects: 48
Study: 35945470

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (systolic blood pressure goal <120 mmHg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard blood pressure lowering (<140 mmHg)
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 9361
Study: 35945477

Group type: EXPERIMENTAL
Intervention: Tracheostomy (20% male vs 14% female)
Number of subjects: 3159

Group type: EXPERIMENTAL
Intervention: Vasopressor therapy (69% male vs 62% female)
Number of subjects: 3159

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (17% male vs 11% female)
Number of subjects: 3159

Group type: COMPARATOR
Intervention: 30-day mortality (50% male vs 49% female)
Number of subjects: 3159

Group type: COMPARATOR
Intervention: 30-day mortality after adjustment for disease severity, frailty, age and treatment limitations
Number of subjects: 3159
Study: 35945517

Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.10-0.20 mg/kg/week
Number of subjects: 510

Group type: COMPARATOR
Intervention: PEG-rhGH 0.10-0.14 mg/kg/week (Group A)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: PEG-rhGH 0.15-0.20 mg/kg/week (Groups B, C, D)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: PEG-rhGH based on IGF-1 status
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: PEG-rhGH
Number of subjects: 510
Study: 35945547

Group type: EXPERIMENTAL
Intervention: E7090 (tasurgratinib), administered once daily as an oral single agent in 28-day cycles.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: E7090 (tasurgratinib)
Number of subjects: 45
Study: 35945605

Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDHT) protocol based on achieving an optimal stroke volume, systolic blood pressure > 90 mmHg, and individualized cardiac index.
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic therapy (GDHT) protocol
Number of subjects: 551

Group type: COMPARATOR
Intervention: Standard care treatment (Control Group)
Number of subjects: 551
Study: 35945611

Group type: EXPERIMENTAL
Intervention: Peer-mentor intervention
Number of subjects: 20
Study: 35945625

Group type: EXPERIMENTAL
Intervention: Home-based exercise prehabilitation programme
Number of subjects: 42
Study: 35945943

Group type: EXPERIMENTAL
Intervention: SPIN-HAND Program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 40
Study: 35946431

Group type: EXPERIMENTAL
Intervention: Ruxolitinib with lenalidomide and methylprednisolone
Number of subjects: 49
Study: 35946927

Group type: EXPERIMENTAL
Intervention: Empagliflozin/linagliptin fixed-dose combination (FDC)
Number of subjects: 1146
Study: 35947027

Group type: EXPERIMENTAL
Intervention: Immunotherapy in the adjuvant setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-in-class, highly selective inhibitor of KRAS G12C
Number of subjects: 0
Study: 35947046

Group type: COMPARATOR
Intervention: Betamimetics
Number of subjects: 13697

Group type: COMPARATOR
Intervention: COX inhibitors
Number of subjects: 13697

Group type: COMPARATOR
Intervention: Calcium channel blockers
Number of subjects: 13697

Group type: COMPARATOR
Intervention: Magnesium sulphate
Number of subjects: 13697

Group type: COMPARATOR
Intervention: Oxytocin receptor antagonists
Number of subjects: 13697

Group type: COMPARATOR
Intervention: Nitric oxide donors
Number of subjects: 13697

Group type: COMPARATOR
Intervention: Combinations of tocolytics
Number of subjects: 13697
Study: 35947087

Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion
Number of subjects: 0
Study: 35947304

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-directed transgastric ERCP (EDGE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Other options offered (Laparoscopy-assisted ERCP, Single-Balloon ERCP, Percutaneous drainage)
Number of subjects: 36
Study: 35947435

Group type: EXPERIMENTAL
Intervention: Ex vivo MRI angiography with contrast agent injection in the umbilical cord
Number of subjects: 100
Study: 35947992

Group type: EXPERIMENTAL
Intervention: MyPROSLE (omic-based analytical workflow)
Number of subjects: 6850

Group type: EXPERIMENTAL
Intervention: MyPROSLE
Number of subjects: 6850
Study: 35948252

Group type: EXPERIMENTAL
Intervention: GOLD group B (high pulmonary symptoms)
Number of subjects: 2664

Group type: EXPERIMENTAL
Intervention: GOLD group D (high pulmonary symptoms and high COPD exacerbation risk)
Number of subjects: 2664

Group type: COMPARATOR
Intervention: Control group (ever smokers without COPD)
Number of subjects: 2664
Study: 35948291

Group type: EXPERIMENTAL
Intervention: Trust in the surgeon and communication style during preoperative consultation and postoperative encounters.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: New strategies to improve language practices and surgeon-patient interaction.
Number of subjects: 80
Study: 35948294

Group type: COMPARATOR
Intervention: Full checklist completion
Number of subjects: 5677

Group type: COMPARATOR
Intervention: Designation of a checklist coordinator
Number of subjects: 5677

Group type: COMPARATOR
Intervention: Incomplete checklist completion
Number of subjects: 5677
Study: 35948301

Group type: EXPERIMENTAL
Intervention: Non-OSA sleep disorders
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Self-report, capacity assessments, and performance measures
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Wrist actigraphy, sleep diaries, overnight oximetry, sleep disorders screening questionnaires
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 10-meter walk test, Stroke Impact Scale, Barthel index, modified Rankin scale
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Leg accelerometry, community trips via GPS data and activity logs
Number of subjects: 200
Study: 35948378

Group type: EXPERIMENTAL
Intervention: Universal screening for SARS-CoV-2 among hospitalized patients
Number of subjects: 15690

Group type: EXPERIMENTAL
Intervention: Factors associated with a positive test
Number of subjects: 15690
Study: 35948604

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study: 35948844

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol
Number of subjects: 1255
Study: 35948879

Group type: EXPERIMENTAL
Intervention: AT LISA tri 839MP multifocal IOL
Number of subjects: 36
Study: 35948919

Group type: EXPERIMENTAL
Intervention: Sequential epirubicin and docetaxel monotherapy
Number of subjects: 51
Study: 35948956

Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 26318

Group type: COMPARATOR
Intervention: Occasional meat-eaters
Number of subjects: 26318

Group type: COMPARATOR
Intervention: Pescatarians
Number of subjects: 26318
Study: 35949152

Group type: EXPERIMENTAL
Intervention: Elevated anxiety
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Elevated depression
Number of subjects: 897

Group type: COMPARATOR
Intervention: Unemployed patients
Number of subjects: 897

Group type: COMPARATOR
Intervention: Patients with a disability pension
Number of subjects: 897

Group type: COMPARATOR
Intervention: Patients with a disability pass
Number of subjects: 897

Group type: COMPARATOR
Intervention: Patients diagnosed 2 to <5 years and ≥5 years
Number of subjects: 897

Group type: COMPARATOR
Intervention: Patients with thoracic STS
Number of subjects: 897

Group type: COMPARATOR
Intervention: Patients with progressive disease
Number of subjects: 897
Study: 35949290

Group type: EXPERIMENTAL
Intervention: GNS561 200 mg BID
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GNS561 50-400 mg Q3W
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GNS561
Number of subjects: 26
Study: 35949358

Group type: EXPERIMENTAL
Intervention: Tirzepatide (GIP/GLP-1R unimolecular dual agonist)
Number of subjects: 13000
Study: 35949367

Group type: EXPERIMENTAL
Intervention: TMAO and its precursors (choline, betaine, carnitine) in maternal and cord plasma
Number of subjects: 1496
Study: 35949912

Group type: EXPERIMENTAL
Intervention: Regenerating peripheral nerve tissue (PNT) implantation to the substantia nigra (SN) during DBS surgery
Number of subjects: 18
Study: 35950205

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily for 12 months
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily after switching from nilotinib
Number of subjects: 13

Group type: COMPARATOR
Intervention: Imatinib (after switch from nilotinib)
Number of subjects: 13
Study: 35950267

Group type: EXPERIMENTAL
Intervention: Telemonitoring programme
Number of subjects: 745

Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 745
Study: 35950603

Group type: EXPERIMENTAL
Intervention: AdAPT-001 monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AdAPT-001 combined with checkpoint inhibitor
Number of subjects: 0
Study: 35950611

Group type: EXPERIMENTAL
Intervention: CTPA
Number of subjects: 149
Study: 35950621

Group type: EXPERIMENTAL
Intervention: Multikinase inhibitors
Number of subjects: 0
Study: 35950901

Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35951488

Group type: EXPERIMENTAL
Intervention: Cultural adaptation of the Adult Day Service Plus intervention for Hispanic/Latino caregivers
Number of subjects: 0
Study: 35951553

Group type: EXPERIMENTAL
Intervention: Nominal group meetings to identify treatment goals and features
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Trust in the healthcare team
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Having good information about options
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Long-term outlook
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall health, quality of life, family and friends, recovery, homecare, and the process of decision-making
Number of subjects: 51
Study: 35951576

Group type: EXPERIMENTAL
Intervention: Scenario 6 (gradient color feedback, world-locked, speed relative to player, disappears over time)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Scenario 5 and 6 (world-locked and speed equal to player speed)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Other scenarios (not specified)
Number of subjects: 25
Study: 35951745

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study: 35952327

Group type: EXPERIMENTAL
Intervention: Rituximab, Lenalidomide, and Ibrutinib (RLI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rituximab, Lenalidomide, and Ibrutinib (RLI) followed by chemotherapy
Number of subjects: 60
Study: 35952579

Group type: EXPERIMENTAL
Intervention: Mild asthma patients experiencing exacerbations
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Exacerbations
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Health status
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Asthma control
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization
Number of subjects: 2004
Study: 35952707

Group type: EXPERIMENTAL
Intervention: De-escalated locoregional radiotherapy according to risk group guidelines (no chest wall radiotherapy in low-risk, local radiotherapy in intermediate-risk, locoregional radiotherapy in high-risk)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Adherence to study guideline for radiotherapy
Number of subjects: 838
Study: 35952709

Group type: EXPERIMENTAL
Intervention: Galunisertib 150 mg twice daily for two 14-day courses before and during chemoradiotherapy.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Galunisertib plus neoadjuvant chemoradiotherapy.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-operative management (control group).
Number of subjects: 38
Study: 35952840

Group type: EXPERIMENTAL
Intervention: First-trimester docosahexaenoic acid and eicosapentaenoic acid supplementation
Number of subjects: 1535

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 1535

Group type: COMPARATOR
Intervention: First-trimester dietary sources of docosahexaenoic acid and eicosapentaenoic acid (among women with no supplementation)
Number of subjects: 1535
Study: 35953136

Group type: EXPERIMENTAL
Intervention: Group 1 PH
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Groups 1-3 PH
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: WSPH groups 1-4
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Group 3 PH
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Group 1, 3, and 4 PH
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: 110 participants
Number of subjects: 1193
Study: 35953259

Group type: EXPERIMENTAL
Intervention: IACA! programme (harm reduction programme based on psychosocial recovery)
Number of subjects: 100
Study: 35953672

Group type: EXPERIMENTAL
Intervention: Bioengineered porcine construct, double crosslinked (BPCDX)
Number of subjects: 20
Study: 35953715

Group type: EXPERIMENTAL
Intervention: GAWMerge protocol for combining genotypes from arrays and whole-genome sequencing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GAWMerge protocol
Number of subjects: 0
Study: 35953737

Group type: EXPERIMENTAL
Intervention: Digital Follow-Up (DFU)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Telephone Follow-Up (TFU)
Number of subjects: 597
Study: 35953839

Group type: EXPERIMENTAL
Intervention: RESHAPE training (service users shared photographic recovery narratives and facilitated social contact)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard mhGAP training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both training arms (RESHAPE and standard mhGAP)
Number of subjects: 28
Study: 35954244

Group type: EXPERIMENTAL
Intervention: CHST7 methylation status
Number of subjects: 0
Study: 35954555

Group type: EXPERIMENTAL
Intervention: Digital Care Program (DCP) consisting of exercise, education, and cognitive-behavioral therapy for 8 weeks
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Digital Care Program (DCP)
Number of subjects: 132
Study: 35957722

Group type: EXPERIMENTAL
Intervention: Single-staged hybrid operation (HO) group
Number of subjects: 132

Group type: COMPARATOR
Intervention: Multi-staged operation (MO) group
Number of subjects: 132
Study: 35957743

Group type: EXPERIMENTAL
Intervention: Central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE) measurements in men.
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Arteriole-to-venule ratio (AVR) measurements.
Number of subjects: 1172
Study: 35957800

Group type: EXPERIMENTAL
Intervention: Antibody positive participants
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: High risk for COVID-19 by GP
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Age > 44 years
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Antibody negative participants
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Self-reported COVID-19 symptoms
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Caucasians
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Non-clinicians
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Age < 44 years
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Staff aged < 44 years
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Self-reported COVID symptoms
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Doctors
Number of subjects: 1082
Study: 35957957

Group type: EXPERIMENTAL
Intervention: Positive psychology (PP) and motivational interviewing (MI) intervention
Number of subjects: 47
Study: 35957960

Group type: EXPERIMENTAL
Intervention: Vigil (1 × 10e6-10e7 cells/dose intradermally, up to 12 doses) and durvalumab (1500 mg/dose intravenous infusion, up to 12 months)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vigil plus durvalumab
Number of subjects: 13
Study: 35958254

Group type: EXPERIMENTAL
Intervention: Fermented oyster (FO) 1,200 mg daily for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fermented oyster (FO)
Number of subjects: 54